A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27416986)

Published in Leukemia on July 15, 2016

Authors

L Jones1, H Carol1, K Evans1, J Richmond1, P J Houghton2, M A Smith3, R B Lock1

Author Affiliations

1: Leukaemia Biology Program, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, New South Wales, Australia.
2: Molecular Medicine, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
3: Cancer Therapy Evaluation Program, NCI, Bethesda, MD, USA.

Associated clinical trials:

A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. | NCT00623870

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | NCT01154816

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) | NCT01451437

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | NCT01037556

Rapamycin in Relapsed Acute Lymphoblastic Leukemia | NCT00874562

Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies | NCT00666081

TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | NCT02484430

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113) | NCT02171260

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | NCT01943682

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | NCT00363272

Articles cited by this

(truncated to the top 100)

Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57

Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21

High drug attrition rates--where are we going wrong? Nat Rev Clin Oncol (2011) 5.67

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20

Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08

Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin (2005) 4.06

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood (2007) 3.14

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99

Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med (2011) 2.03

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92

Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84

New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78

Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res (2007) 1.71

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 1.68

Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66

Declining childhood and adolescent cancer mortality. Cancer (2014) 1.62

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol (2011) 1.61

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol (2009) 1.59

Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.55

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood (2015) 1.52

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther (2010) 1.34

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood (2012) 1.33

Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets (2012) 1.33

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia (2012) 1.33

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30

AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist (2013) 1.29

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res (2007) 1.29

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23

Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol (2014) 1.21

Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood (1993) 1.20

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.20

Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol (2010) 1.20

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 1.16

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer (2010) 1.15

Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc (2010) 1.15

Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.14

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One (2012) 1.14

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res (2012) 1.13

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13

The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood (2011) 1.12

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res (2011) 1.10

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol (2007) 1.09

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 1.04

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03

Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.00

Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther (2008) 1.00

New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol (2013) 1.00

Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation. Exp Hematol (2009) 0.98

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 0.98

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 0.98

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.94

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.93

Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol (2009) 0.93

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer (2011) 0.91

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol (2003) 0.91

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res (2014) 0.91

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer (2014) 0.90

Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol (2002) 0.90

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol (2014) 0.90

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol (2004) 0.88

Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 0.88

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.87

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer (2014) 0.87

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica (2015) 0.87

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.86

Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.85

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.85

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 0.85

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.84

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.84

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.83

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.83

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 0.82

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.82

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin Cancer Res (2015) 0.82

Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.80

Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer (2009) 0.80

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Mol Cancer Ther (2014) 0.80

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.79

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.78

Antibody therapy for pediatric leukemia. Front Oncol (2014) 0.78

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer (2014) 0.77

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.77

New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer? Expert Rev Anticancer Ther (2013) 0.76

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2014) 0.76